BIOPHARMA COMPANIES TYPICALLY TARGET BIG PHARMA AS PARTNERS, but this is not the only strategy worth considering. There are mid-sized, and even small, well-capitalized partners that should be evaluated, who are more likely to focus on your technology, and be more stable partners for the process. Getting attention of Big Pharma is very slow, and if your Champion cycles out, you may have to start all over. Make sure you give the less newsworthy partner careful consideration as you seek funding.
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022